Adult Dosing
Acute bacterial sinusitis
- 400 mg IV q24 hrs x 10 days
Acute bacterial exacerbation of chronic bronchitis
- 400 mg IV q24 hrs x 5 days
Community-acquired pneumonia
- 400 mg IV q24 hrs x 7-14 days
Uncomplicated skin and skin structure infections
- 400 mg IV q24 hrs x 7 days
Complicated skin and skin structure infections
- 400 mg IV q24 hrs x 7–21 days
Complicated intra-abdominal infections
- 400 mg IV q24 hrs x 5-14 days
Bronchiectasis [Not FDA Approved]
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Rapid or bolus IV infusion of moxifloxacin may be associated with severe hypotension and should be avoided
- Should be administered only by intravenous infusion. It is not meant for intramuscular, intrathecal, intra-arterial, intraperitoneal, or subcutaneous administration
- Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients, usually over 60 yrs of age, in kidney, heart, and lung transplant recipients and with the use of concomitant corticosteroid therapy [US Black Box Warning]. Discontinue the treatment if pain, swelling, inflammation or rupture of the tendon occurs
- Fluoroquinolones may exacerbate muscle weakness in patients with MG; avoid prescribing Avelox in persons with a known history of MG [US Black Box Warning]
- Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known QT interval prolongation and in patients with uncorrected electrolyte disorders (hypokalemia or hypomagnesemia)
- Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions that include cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching have been reported in patients receiving therapy with fluoroquinolones. Discontinue immediately at the appearance of any sign of an immediate type I hypersensitivity skin rash or any other manifestations of a hypersensitivity reaction
- Metabolic disturbances associated with hepatic insufficiency may cause QT prolongation
- Central nervous system adverse reactions, including convulsions, dizziness, anxiety, confusion, tremors, nervousness, depression, and insomnia may occur after the first dose. Discontinue the drug and start appropriate therapy if such reaction occurs. Use with caution in patients with known or suspected CNS disorders
- Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of this drug and may range in severity from mild diarrhea to fatal colitis
- Rare cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons have been reported in patients receiving fluoroquinolones
- Moderate to severe photosensitivity reactions have occurred with some fluoroquinolones. Avoid excessive sunlight exposure
- Prescribing Avelox in the absence of a proven or strongly suspected bacterial infections or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria
Cautions: Use cautiously in
- Mild, moderate or severe liver cirrhosis
- Kidney, heart, or lung transplant patients
- Concurrent use of corticosteroids
- known or suspected central nervous system disorder
- Concurrent use of class IA or class III antiarrhythmics
- Congenital long QT syndrome
- Patients with ongoing proarrhythmic conditions such as clinically significant bradycardia, acute myocardial ischemia
- Seizure disorder
- Low seizure threshold
- Dehydration
Supplemental Patient Information
- Caution against operating machinery, driving a vehicle, or doing other activities that require mental alertness
- Avoid exposure to intense sunlight by using a sunscreen and wearing protective clothing in order to prevent photosensitivity reactions
Pregnancy Category:C
Breastfeeding: Fluoroquinolones have not been used in infants because of concern about adverse effects on the infants' developing joints. Short-term use of moxifloxacin is acceptable in nursing mothers. However, it is preferable to use an alternate drug for which safety information is available. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 11 February 2011). According to the manufacturer's data; moxifloxacin may be excreted in human milk. Due to the potential for possible serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of the drug taking into account the importance of the drug to the mother.
